Free Trial

Aardvark Therapeutics (AARD) Competitors

Aardvark Therapeutics logo
$13.04 -0.88 (-6.32%)
As of 07/8/2025 04:00 PM Eastern

AARD vs. GPCR, PAHC, ABCL, AMPH, NTLA, WVE, ELVN, AUPH, ARDX, and VERV

Should you be buying Aardvark Therapeutics stock or one of its competitors? The main competitors of Aardvark Therapeutics include Structure Therapeutics (GPCR), Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), Amphastar Pharmaceuticals (AMPH), Intellia Therapeutics (NTLA), WAVE Life Sciences (WVE), Enliven Therapeutics (ELVN), Aurinia Pharmaceuticals (AUPH), Ardelyx (ARDX), and Verve Therapeutics (VERV). These companies are all part of the "pharmaceutical products" industry.

Aardvark Therapeutics vs. Its Competitors

Structure Therapeutics (NASDAQ:GPCR) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

Structure Therapeutics currently has a consensus price target of $76.17, suggesting a potential upside of 306.44%. Aardvark Therapeutics has a consensus price target of $33.00, suggesting a potential upside of 153.07%. Given Structure Therapeutics' higher possible upside, equities analysts plainly believe Structure Therapeutics is more favorable than Aardvark Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Structure Therapeutics
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
Aardvark Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

91.8% of Structure Therapeutics shares are held by institutional investors. 9.4% of Structure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Aardvark Therapeutics had 5 more articles in the media than Structure Therapeutics. MarketBeat recorded 8 mentions for Aardvark Therapeutics and 3 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.56 beat Aardvark Therapeutics' score of 0.49 indicating that Structure Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Structure Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aardvark Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Structure TherapeuticsN/AN/A-$122.53M-$0.87-21.54
Aardvark TherapeuticsN/AN/A-$20.59MN/AN/A

Aardvark Therapeutics' return on equity of 0.00% beat Structure Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Structure TherapeuticsN/A -16.35% -15.71%
Aardvark Therapeutics N/A N/A N/A

Summary

Structure Therapeutics beats Aardvark Therapeutics on 5 of the 9 factors compared between the two stocks.

Get Aardvark Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AARD and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AARD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AARD vs. The Competition

MetricAardvark TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$302.01M$2.87B$5.47B$8.95B
Dividend YieldN/A2.46%5.25%4.04%
P/E RatioN/A20.8026.9620.11
Price / SalesN/A286.27430.20119.79
Price / CashN/A41.1936.8257.86
Price / BookN/A7.487.985.56
Net Income-$20.59M-$55.04M$3.16B$248.40M
7 Day Performance-3.55%2.44%2.39%4.67%
1 Month Performance11.64%1.90%2.18%6.64%
1 Year PerformanceN/A4.35%33.82%21.31%

Aardvark Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AARD
Aardvark Therapeutics
N/A$13.04
-6.3%
$33.00
+153.1%
N/A$302.01MN/A0.0018
GPCR
Structure Therapeutics
2.6781 of 5 stars
$20.62
+0.9%
$76.17
+269.4%
-49.7%$1.17BN/A-23.70136
PAHC
Phibro Animal Health
3.6799 of 5 stars
$27.99
+0.2%
$21.80
-22.1%
+71.9%$1.13B$1.02B35.891,940Trending News
Analyst Upgrade
ABCL
AbCellera Biologics
2.5514 of 5 stars
$3.81
+1.5%
$8.33
+119.0%
+41.5%$1.12B$28.83M-6.79500News Coverage
Analyst Forecast
AMPH
Amphastar Pharmaceuticals
4.4152 of 5 stars
$23.18
-1.7%
$32.33
+39.5%
-39.5%$1.11B$731.97M8.402,028
NTLA
Intellia Therapeutics
4.6944 of 5 stars
$10.72
-0.1%
$33.37
+211.4%
-51.5%$1.11B$57.88M-2.05600
WVE
WAVE Life Sciences
4.4295 of 5 stars
$6.97
+3.3%
$20.50
+194.1%
+27.1%$1.05B$108.30M-8.30240
ELVN
Enliven Therapeutics
2.6659 of 5 stars
$20.68
+0.2%
$41.20
+99.3%
-11.2%$1.01BN/A-10.7750
AUPH
Aurinia Pharmaceuticals
2.5668 of 5 stars
$7.57
+1.0%
$11.50
+52.0%
+34.8%$1.01B$235.13M27.02300
ARDX
Ardelyx
4.4333 of 5 stars
$4.30
+2.5%
$10.89
+153.5%
-17.8%$1.00B$333.61M-19.5290
VERV
Verve Therapeutics
3.4646 of 5 stars
$11.23
+0.1%
$14.57
+29.8%
+96.3%$999.29M$59.61M-5.32110

Related Companies and Tools


This page (NASDAQ:AARD) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners